DarioHealth (NASDAQ:DRIO) Share Price Crosses Below 200-Day Moving Average - Time to Sell?

Key Points

• Price breach: DarioHealth shares dropped below their 200-day moving average of $10.88, trading as low as $7.22 and last at $7.45, indicating technical weakness.
• Mixed analyst view: The consensus rating is "Hold" with a $35 consensus target, but recent activity includes a downgrade to "sell" from Wall Street Zen and Stifel cutting its target to $10.
• Company fundamentals: Market cap is $54.39 million with a negative P/E (-0.71) but healthy liquidity (current ratio 3.76, quick ratio 3.30); about 33% of shares are held by institutions, with recent stake increases from Geode and XTX.

DarioHealth Corp. (NASDAQ:DRIO - Get Free Report)'s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.88 and traded as low as $7.22. DarioHealth shares last traded at $7.45, with a volume of 3,940 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DRIO. Wall Street Zen cut shares of DarioHealth from a "hold" rating to a "sell" rating in a report on Sunday, January 25th. Stifel Nicolaus cut their target price on shares of DarioHealth from $16.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, March 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DarioHealth presently has a consensus rating of "Hold" and a consensus target price of $35.00.

DarioHealth Stock Up 2.1%

The business's fifty day moving average price is $8.52 and its 200 day moving average price is $10.88. The firm has a market capitalization of $54.39 million, a price-to-earnings ratio of -0.71 and a beta of 1.09. The company has a current ratio of 3.76, a quick ratio of 3.30 and a debt-to-equity ratio of 0.45.

Hedge Funds Weigh In On DarioHealth

Several institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in DarioHealth in the 4th quarter valued at $35,000. Geode Capital Management LLC increased its stake in DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock valued at $564,000 after buying an additional 31,063 shares during the period. Finally, XTX Topco Ltd increased its stake in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock valued at $42,000 after buying an additional 43,513 shares during the period. 33.39% of the stock is owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.